Pacira BioSciences (PCRX) Q4 2024 earnings summary

Executive summary

• Achieved record 2024 revenues of $701 million, reaching the high end of guidance and up 4% year-over-year, with strong commercial execution and expanded reimbursement for key products.

• Advanced the 5x30 strategy to drive double-digit CAGR in product revenues, gross margin expansion, and five novel clinical programs by 2030.

• Acquired GQ Bio, adding a gene therapy platform, preclinical pipeline for musculoskeletal diseases, and eliminating future milestone payments.

• Secured expanded reimbursement for EXPAREL and iovera° under the NOPAIN Act, with new product-specific codes and GPO partnerships.

• Reported full-year GAAP net loss of $99.6 million, driven by a $163.2 million goodwill impairment; adjusted EBITDA was $223.9 million, up 4%.

Financial highlights

• FY24 total revenue reached $701M; Q4 revenue was $187.3M, up 3% year-over-year.

• EXPAREL FY24 revenue: $549M; ZILRETTA: $118.1M; iovera°: $22.8M.

• Q4 adjusted EBITDA was $62.5M; full-year adjusted EBITDA was $223.9M; non-GAAP gross margin for FY24 was 76%, Q4 was 79%.

• Ended 2024 with $484.6M in cash and investments; cash from operations was $189.4M.

• Non-GAAP net income for 2024 was $157.7M ($3.41 per basic share).

Outlook and guidance

• 2025 revenue guidance: $725M–$765M, with meaningful NOPAIN uptake expected in the second half.

• Non-GAAP gross margin guidance: 76%–78%; R&D expense: $90M–$105M; SG&A: $290M–$320M.

• DTC marketing pilots for Exparel to begin in H1 2025, with spend adjusted based on ROI.

• Stock-based compensation forecasted at $56–$61M; depreciation expense for 2025 expected at ~$30M.

• Targeting double-digit CAGR in product revenue and 5-point gross margin improvement over 2024 by 2030.